MX385385B - Inhibidores de bmi-1 de pirimidina inversa sustituida. - Google Patents
Inhibidores de bmi-1 de pirimidina inversa sustituida.Info
- Publication number
- MX385385B MX385385B MX2015006469A MX2015006469A MX385385B MX 385385 B MX385385 B MX 385385B MX 2015006469 A MX2015006469 A MX 2015006469A MX 2015006469 A MX2015006469 A MX 2015006469A MX 385385 B MX385385 B MX 385385B
- Authority
- MX
- Mexico
- Prior art keywords
- bmi
- inhibitors
- substituted reverse
- reverse pyrimidine
- inhibit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hematology (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261728907P | 2012-11-21 | 2012-11-21 | |
| PCT/US2013/071132 WO2014081906A2 (en) | 2012-11-21 | 2013-11-21 | Substituted reverse pyrimidine bmi-1 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015006469A MX2015006469A (es) | 2015-10-29 |
| MX385385B true MX385385B (es) | 2025-03-18 |
Family
ID=50776672
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015006469A MX385385B (es) | 2012-11-21 | 2013-11-21 | Inhibidores de bmi-1 de pirimidina inversa sustituida. |
| MX2021009892A MX2021009892A (es) | 2012-11-21 | 2015-05-21 | Inhibidores de bmi-1 de pirimidina inversa sustituida. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009892A MX2021009892A (es) | 2012-11-21 | 2015-05-21 | Inhibidores de bmi-1 de pirimidina inversa sustituida. |
Country Status (32)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6412503B2 (ja) * | 2012-11-21 | 2018-10-24 | ピーティーシー セラピューティクス， インコーポレイテッド | 置換逆ピリミジンＢｍｉ−１阻害剤 |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US10376510B2 (en) * | 2013-07-11 | 2019-08-13 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| KR102232595B1 (ko) | 2013-08-30 | 2021-03-26 | 피티씨 테라퓨틱스, 인크. | 치환된 피리미딘 bmi-1 저해제 |
| EP3071553A4 (en) | 2013-11-21 | 2017-08-02 | PTC Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
| CN108351862B (zh) | 2015-08-11 | 2023-08-22 | 科格诺亚公司 | 利用人工智能和用户输入来确定发育进展的方法和装置 |
| US10851082B2 (en) | 2015-10-28 | 2020-12-01 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) |
| US11972336B2 (en) | 2015-12-18 | 2024-04-30 | Cognoa, Inc. | Machine learning platform and system for data analysis |
| CA3010615C (en) * | 2016-01-14 | 2024-02-20 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
| WO2018090009A1 (en) | 2016-11-14 | 2018-05-17 | Cognoa, Inc. | Methods and apparatus for evaluating developmental conditions and providing control over coverage and reliability |
| WO2018148365A1 (en) * | 2017-02-09 | 2018-08-16 | Cognoa, Inc. | Platform and system for digital personalized medicine |
| KR20200035292A (ko) | 2017-08-01 | 2020-04-02 | 피티씨 테라퓨틱스, 인크. | 혈액 암 치료에 사용하기 위한 dhodh 억제제 |
| EP3564235A1 (en) * | 2018-05-03 | 2019-11-06 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2) |
| JP2021535198A (ja) * | 2018-08-17 | 2021-12-16 | ピーティーシー セラピューティクス， インコーポレイテッド | 膵臓癌を治療する方法 |
| CN109988172B (zh) * | 2019-01-10 | 2020-09-29 | 石家庄学院 | 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法 |
| AU2020209767B2 (en) * | 2019-01-15 | 2025-03-06 | Ptc Therapeutics, Inc. | Method for treating an acute myeloid leukemia |
| MX2021010398A (es) * | 2019-02-28 | 2022-01-18 | Ptc Therapeutics Inc | Metodo para tratar un mieloma multiple. |
| MX2021010906A (es) * | 2019-03-11 | 2021-10-01 | Ptc Therapeutics Inc | Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas. |
| AU2020248351B2 (en) | 2019-03-22 | 2025-09-25 | Cognoa, Inc. | Personalized digital therapy methods and devices |
| EA202192349A1 (ru) * | 2019-03-27 | 2022-02-01 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Комбинации, пригодные в способе лечения саркомы |
| JP2022527925A (ja) * | 2019-04-02 | 2022-06-07 | ヒノバ ファーマシューティカルズ インコーポレイテッド | 芳香族アミン系化合物と、該化合物のａｒおよびｂｒｄ４二重阻害剤ならびに調節剤の製造における使用 |
| CA3153086A1 (en) | 2019-09-06 | 2021-03-11 | Cognoa, Inc. | Methods, systems, and devices for the diagnosis of behavioral disorders, developmental delays, and neurologic impairments |
| US12245355B2 (en) | 2021-02-19 | 2025-03-04 | Mevion Medical Systems, Inc. | Gantry for a particle therapy system |
| US20240120050A1 (en) * | 2022-10-07 | 2024-04-11 | Insight Direct Usa, Inc. | Machine learning method for predicting a health outcome of a patient using video and audio analytics |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH593266A5 (enExample) | 1973-09-20 | 1977-11-30 | Delalande Sa | |
| AU688087B2 (en) | 1994-08-13 | 1998-03-05 | Yuhan Corporation | Novel pyrimidine derivatives and processes for the preparation thereof |
| IN188411B (enExample) | 1997-03-27 | 2002-09-21 | Yuhan Corp | |
| KR100272471B1 (ko) | 1998-11-17 | 2000-11-15 | 김선진 | 신규의 피리미딘 유도체 및 그의 제조방법 |
| GB9905075D0 (en) * | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| AU5636900A (en) | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| JP2003511378A (ja) | 1999-10-07 | 2003-03-25 | アムジエン・インコーポレーテツド | トリアジン系キナーゼ阻害薬 |
| AU7922900A (en) | 1999-10-27 | 2001-05-08 | Novartis Ag | Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use |
| HUP0301117A3 (en) | 2000-02-17 | 2004-01-28 | Amgen Inc Thousand Oaks | Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them |
| AU2001242629B2 (en) | 2000-03-29 | 2005-08-11 | Cyclacel Limited | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders |
| ES2266258T3 (es) | 2000-09-15 | 2007-03-01 | Vertex Pharmaceuticals Incorporated | Compuestos de pirazol utiles como inhibidores de proteina cinasas. |
| AU9458401A (en) | 2000-09-20 | 2002-04-02 | Ortho Mcneil Pharm Inc | Pyrazine derivatives as modulators of tyrosine kinases |
| US6716851B2 (en) * | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
| AU2002228922A1 (en) * | 2000-12-12 | 2002-06-24 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| WO2002048148A2 (en) | 2000-12-15 | 2002-06-20 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| BR0207096A (pt) | 2001-02-20 | 2004-01-20 | Astrazeneca Ab | Uso de um composto, compostos, formulação farmacêutica, e, método de tratamento e/ou profilaxia de condições associadas com a inibição de glicogênio sintase quinase-3 |
| US20030165873A1 (en) | 2001-03-02 | 2003-09-04 | Come Jon H. | Three hybrid assay system |
| CA2450555A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| US6689778B2 (en) | 2001-07-03 | 2004-02-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of Src and Lck protein kinases |
| WO2003011837A1 (en) | 2001-08-01 | 2003-02-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AU2003212634A1 (en) * | 2002-03-11 | 2003-09-22 | Zetiq Technologies Ltd. | Compounds useful in the treatment of cancer |
| CA2486187C (en) | 2002-05-23 | 2013-02-19 | Cytopia Pty Ltd. | Kinase inhibitors |
| US7494997B2 (en) | 2002-06-28 | 2009-02-24 | Nippon Shinyaku Co., Ltd. | Amide derivative |
| GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| WO2004007407A2 (en) * | 2002-07-11 | 2004-01-22 | Fluorous Technologies Incorporated | Fluorous tagging and scavenging reactants and methods of synthesis and use thereof |
| US20040110821A1 (en) * | 2002-08-07 | 2004-06-10 | Konkel Michael J. | GAL3 receptor antagonists for the treatment of affective disorders |
| UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| AU2003301302A1 (en) | 2002-10-15 | 2004-05-04 | Smithkline Beecham Corporation | Pyradazine compounds as gsk-3 inhibitors |
| US7169781B2 (en) | 2003-10-17 | 2007-01-30 | Hoffmann-La Roche Inc. | Imidazole derivatives and their use as pharmaceutical agents |
| US20080207613A1 (en) | 2004-01-12 | 2008-08-28 | Cytopia Research Pty Ltd | Selective Kinase Inhibitors |
| JP2007520558A (ja) | 2004-02-04 | 2007-07-26 | スミスクライン・ビーチャム・コーポレイション | キナーゼ阻害剤として有用なピリミジノン化合物 |
| US7507826B2 (en) * | 2004-03-30 | 2009-03-24 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
| JP2006045119A (ja) | 2004-08-04 | 2006-02-16 | Toray Ind Inc | ピラジン誘導体及びそれを有効成分とする腎炎治療薬 |
| US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| EP1854793A4 (en) | 2005-02-28 | 2011-01-26 | Japan Tobacco Inc | NEW AMINOPYRIDEIN COMPOUND WITH SYK-HEMDERING EFFECT |
| WO2006099231A1 (en) | 2005-03-10 | 2006-09-21 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives for treatment of hyperproliferative disorders |
| US20080039450A1 (en) | 2006-06-22 | 2008-02-14 | Jensen Annika J | Compounds |
| CN101516873A (zh) * | 2006-10-03 | 2009-08-26 | 神经研究公司 | 用作钾通道调节剂的吲唑基衍生物 |
| AU2007304195A1 (en) | 2006-10-03 | 2008-04-10 | Neurosearch A/S | Indazolyl derivatives useful as potassium channel modulating agents |
| ES2383370T3 (es) | 2006-10-19 | 2012-06-20 | Signal Pharmaceuticals Llc | Compuestos de heteroarilo, sus composiciones y uso de los mismos como inhibidores de proteína quinasa |
| WO2008079933A2 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
| TW200902010A (en) | 2007-01-26 | 2009-01-16 | Smithkline Beecham Corp | Anthranilamide inhibitors of aurora kinase |
| EP2121633A2 (en) | 2007-02-12 | 2009-11-25 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| WO2008132502A1 (en) | 2007-04-25 | 2008-11-06 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer |
| GB0714573D0 (en) | 2007-07-26 | 2007-09-05 | Imp Innovations Ltd | Marker gene |
| WO2009037247A1 (en) | 2007-09-17 | 2009-03-26 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
| MX2010005300A (es) | 2007-11-16 | 2010-06-25 | Incyte Corp | 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpir imidin-2-aminas como inhibidores de cinasas janus. |
| JP2011506303A (ja) | 2007-12-07 | 2011-03-03 | ノバルティス アーゲー | ピラゾール誘導体およびサイクリン依存性キナーゼの阻害剤としてのその使用 |
| DE102008005493A1 (de) | 2008-01-22 | 2009-07-23 | Merck Patent Gmbh | 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate |
| GB0801416D0 (en) | 2008-01-25 | 2008-03-05 | Piramed Ltd | Pharmaceutical compounds |
| JP2011518219A (ja) | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ， インコーポレイテッド | タンパク質キナーゼの阻害剤 |
| ES2605815T3 (es) * | 2008-07-01 | 2017-03-16 | Ptc Therapeutics, Inc. | Moduladores de la expresión de la proteína Bmi-1 |
| JP5576370B2 (ja) | 2008-08-06 | 2014-08-20 | ファイザー・インク | Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物 |
| CN102177154A (zh) * | 2008-09-02 | 2011-09-07 | 神经研究公司 | 吡唑基-嘧啶衍生物及其作为钾通道调节剂的应用 |
| WO2010061903A1 (ja) * | 2008-11-27 | 2010-06-03 | 塩野義製薬株式会社 | Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体 |
| WO2010092962A1 (ja) | 2009-02-12 | 2010-08-19 | アステラス製薬株式会社 | へテロ環誘導体 |
| AU2010229468A1 (en) | 2009-03-27 | 2011-10-13 | Vetdc, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| EP2435435B1 (en) | 2009-05-27 | 2014-01-29 | AbbVie Inc. | Pyrimidine inhibitors of kinase activity |
| WO2010144416A1 (en) | 2009-06-08 | 2010-12-16 | Gaeta Federico C A | SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY |
| DK2442809T3 (en) | 2009-06-17 | 2016-12-19 | Vertex Pharma | Inhibitors of the replication of influenza virus |
| US8486939B2 (en) | 2009-07-07 | 2013-07-16 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| JP2012533553A (ja) | 2009-07-15 | 2012-12-27 | アボット・ラボラトリーズ | ピロロピリジン系キナーゼ阻害薬 |
| EP2454262B1 (en) | 2009-07-15 | 2014-05-14 | Abbott Laboratories | Pyrrolopyrazine inhibitors of kinases |
| JP2011136925A (ja) | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | 含窒素二環性化合物 |
| TWI523852B (zh) | 2010-01-12 | 2016-03-01 | Ａｂ科學公司 | 經取代之唑衍生物、含彼之組合物及其用途 |
| UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| ES2365960B1 (es) | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| KR101788903B1 (ko) * | 2010-08-19 | 2017-10-23 | 에프. 호프만-라 로슈 아게 | 체세포의 유도된 재프로그래밍된 신경 줄기 세포 (ｉｒｎｓｃｓ) 로의 전환 |
| CA2812081A1 (en) | 2010-09-13 | 2012-03-22 | Novartis Ag | Triazine-oxadiazoles |
| WO2012050884A2 (en) | 2010-09-28 | 2012-04-19 | President And Fellows Of Harvard College | Cardiac glycosides are potent inhibitors of interferon-beta gene expression |
| US9090593B2 (en) * | 2010-12-09 | 2015-07-28 | Amgen Inc. | Bicyclic compounds as Pim inhibitors |
| CN103402997B (zh) | 2011-02-25 | 2015-08-26 | 柳韩洋行 | 二氨基嘧啶衍生物及其制备方法 |
| ES2698847T3 (es) * | 2011-07-07 | 2019-02-06 | Merck Patent Gmbh | Azaheterociclos sustituidos para el tratamiento del cáncer |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| JP6412503B2 (ja) | 2012-11-21 | 2018-10-24 | ピーティーシー セラピューティクス， インコーポレイテッド | 置換逆ピリミジンＢｍｉ−１阻害剤 |
| US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
| MX2021010906A (es) * | 2019-03-11 | 2021-10-01 | Ptc Therapeutics Inc | Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas. |
-
2013
- 2013-11-21 JP JP2015544124A patent/JP6412503B2/ja active Active
- 2013-11-21 SG SG10201600149VA patent/SG10201600149VA/en unknown
- 2013-11-21 PE PE2015000665A patent/PE20151413A1/es unknown
- 2013-11-21 TW TW102142555A patent/TWI623531B/zh not_active IP Right Cessation
- 2013-11-21 KR KR1020227002513A patent/KR102455889B1/ko active Active
- 2013-11-21 AU AU2013348009A patent/AU2013348009C1/en active Active
- 2013-11-21 KR KR1020217020963A patent/KR102356487B1/ko active Active
- 2013-11-21 WO PCT/US2013/071132 patent/WO2014081906A2/en not_active Ceased
- 2013-11-21 UA UAA201505533A patent/UA118094C2/uk unknown
- 2013-11-21 SG SG11201503982XA patent/SG11201503982XA/en unknown
- 2013-11-21 CN CN202010080540.0A patent/CN111423417B/zh active Active
- 2013-11-21 EA EA201590992A patent/EA031405B1/ru unknown
- 2013-11-21 DK DK13857326.6T patent/DK2922828T3/da active
- 2013-11-21 CU CU2015000053A patent/CU24387B1/es unknown
- 2013-11-21 BR BR112015011760-0A patent/BR112015011760B1/pt active IP Right Grant
- 2013-11-21 CA CA2892045A patent/CA2892045C/en active Active
- 2013-11-21 US US14/443,911 patent/US10428050B2/en active Active
- 2013-11-21 KR KR1020227035587A patent/KR20220143164A/ko not_active Ceased
- 2013-11-21 HK HK16103069.2A patent/HK1215032A1/zh unknown
- 2013-11-21 NZ NZ74660713A patent/NZ746607A/en unknown
- 2013-11-21 AR ARP130104300A patent/AR093579A1/es active IP Right Grant
- 2013-11-21 EP EP13857326.6A patent/EP2922828B1/en active Active
- 2013-11-21 KR KR1020157016184A patent/KR102275676B1/ko not_active Expired - Fee Related
- 2013-11-21 MX MX2015006469A patent/MX385385B/es unknown
- 2013-11-21 NZ NZ70890913A patent/NZ708909A/en unknown
- 2013-11-21 PT PT138573266T patent/PT2922828T/pt unknown
- 2013-11-21 EA EA201890142A patent/EA035349B1/ru not_active IP Right Cessation
- 2013-11-21 MA MA38208A patent/MA38208B1/fr unknown
- 2013-11-21 PH PH1/2015/501130A patent/PH12015501130B1/en unknown
- 2013-11-21 ES ES13857326T patent/ES2821529T3/es active Active
- 2013-11-21 CN CN201380070973.6A patent/CN104918919A/zh active Pending
- 2013-11-21 PL PL13857326T patent/PL2922828T3/pl unknown
-
2015
- 2015-05-18 IL IL238871A patent/IL238871B/en active IP Right Grant
- 2015-05-20 CL CL2015001377A patent/CL2015001377A1/es unknown
- 2015-05-21 EC ECIEPI201519948A patent/ECSP15019948A/es unknown
- 2015-05-21 SA SA517381847A patent/SA517381847B1/ar unknown
- 2015-05-21 MX MX2021009892A patent/MX2021009892A/es unknown
- 2015-05-21 NI NI201500072A patent/NI201500072A/es unknown
- 2015-05-22 ZA ZA2015/03642A patent/ZA201503642B/en unknown
- 2015-06-05 CR CR20150294A patent/CR20150294A/es unknown
-
2018
- 2018-09-28 JP JP2018183173A patent/JP6617186B2/ja active Active
-
2019
- 2019-03-10 IL IL265253A patent/IL265253A/en unknown
- 2019-09-26 US US16/583,442 patent/US11180483B2/en not_active Expired - Fee Related
- 2019-11-11 JP JP2019203706A patent/JP6918898B2/ja not_active Expired - Fee Related
-
2021
- 2021-11-10 US US17/523,480 patent/US20220064150A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009892A (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida. | |
| MX370588B (es) | Inhibidores de la bmi-1 de pirimidina sustituida. | |
| EA201692338A1 (ru) | Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы | |
| EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
| ECSP17016797A (es) | Indazoles sustituidos con benzilo como inhibidores de bub1 | |
| EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
| UA116920C2 (uk) | Інгібітори fgfr4 | |
| MX375625B (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
| MX2018001890A (es) | Compuestos biciclicos como inhibidores de autotaxina (atx). | |
| MX372962B (es) | Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca). | |
| CR20150524A (es) | Compuestos de heteroarilo y sus usos | |
| MX374558B (es) | Compuestos de heteroarilo y sus usos. | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| EA201790921A1 (ru) | Замещенные производные 2-анилинпиримидина в качестве модуляторов egfr | |
| MX2018000880A (es) | Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r). | |
| MX2018002217A (es) | Nuevos compuestos biciclicos como inhibidores de autotaxina (atx). | |
| EA201692521A1 (ru) | Пиразольные соединения и их применение в качестве блокаторов кальциевых каналов т-типа | |
| MX2019007339A (es) | Compuestos de pirazolopirimidina y metodos de uso de los mismos. | |
| MX2018007219A (es) | Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
| MX2015013414A (es) | N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa. | |
| EA201590656A1 (ru) | Азаиндолины | |
| EA202091691A1 (ru) | ТВЕРДЫЕ ФОРМЫ ЗАМЕЩЕННЫХ 5,6-ДИГИДРО-6-ФЕНИЛБЕНЗО[f]ИЗОХИНОЛИН-2-АМИНОВЫХ СОЕДИНЕНИЙ | |
| UY34099A (es) | ?composición de agentes de coalescencia?. | |
| EA201792380A1 (ru) | Новые ингибиторы epha4, нацеленные на его лиганд-связывающий домен | |
| PH12018500406A1 (en) | Bicyclic compounds as atx inhibitors |